ARCA BIOPHARMA INC (ABIO)

US00211Y5069 - Common Stock

2.4  -0.1 (-4%)

After market: 2.48 +0.08 (+3.33%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
N/AN/AN/A
EBITDA
YoY % growth
-9.68M-11.44M
-18.18%
-16.59M
-45.02%
-18.68M
-12.60%
-8.1M
56.64%
-5.79M
28.52%
-9.76M
-68.57%
-19.319M
-97.94%
-10.576M
45.26%
-7.281M
31.16%
N/AN/AN/A
EBIT
YoY % growth
-9.69M-11.46M
-18.27%
-16.61M
-44.94%
-18.71M
-12.64%
-8.12M
56.60%
-5.81M
28.45%
-9.77M
-68.16%
-19.335M
-97.90%
-10.596M
45.20%
-7.296M
31.14%
N/AN/AN/A
Operating Margin
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
N/AN/AN/AN/A-10.08
71.85%
-4.53
55.06%
-2.50
44.81%
N/AN/AN/AN/AN/A
-20.51%
N/A
-30.50%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
-0.10
37.50%
%
Q3 2022
Q2Q % growth
-0.16
51.52%
%
Q2 2022
Q2Q % growth
-0.22
35.29%
%
Q1 2022
Q2Q % growth
-0.23
30.30%
%
Q3 2021
Q2Q % growth
-0.33 %
Q2 2021
Q2Q % growth
-0.34
53.42%
%
Q1 2021
Q2Q % growth
-0.33
60.24%
%
Q4 2020
Q2Q % growth
-0.61
20.78%
%
Q3 2020
Q2Q % growth
-0.33
56.58%
%
Q2 2020
Q2Q % growth
-0.73
35.96%
-2.631.9072.26%
Q1 2020
Q2Q % growth
-0.83
55.38%
-2.081.2560.11%
Q4 2019
Q2Q % growth
-0.77 -1.010.2423.75%
Q3 2019
Q2Q % growth
-0.76 -1.330.5742.68%
Q2 2019
Q2Q % growth
-1.14 -1.900.7639.91%
Q1 2019
Q2Q % growth
-1.86 -2.020.167.90%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A